About Amgen Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.amgen.com/
Frequently Asked Questions
What is the 52-week range for AMGN?
The 52-week high is $447.03 and the 52-week low is $283.
What is the P/E ratio for AMGN?
The Price to Earnings (P/E) ratio is 25.09.
What is the dividend yield for AMGN?
The indicated annual dividend yield is 3.21%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 89.32%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 22.95%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 20.36.
Analyst Recommendation Trends
Wall Street analyst consensus for AMGN over the last few months:
Latest AMGN News
Friday's session: top gainers and losers in the dow jones index
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
What's going on in today's session: dow jones movers
Curious about the top performers within the dow jones index in the middle of the day on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch
JNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.
3 Dow Jones Stocks with Exciting Potential
The biggest names in corporate America call the Dow Jones (^DJI) home, but only a handful are still growing at a strong pace. Some of these blue-chip stocks are standing out by adapting to change and driving shareholder value.
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock
October 1, 2026 records indicate that Representative David Taylor filed a purchase of Amgen (NASDAQ:AMGN), valued between $3,003 and $45,000. According to the October filing, the transaction occurred on September 22,
GLP-1s: Still Early In The Growth Story
The GLP-1 market continues to expand rapidly yet remains in the early stages of growth. The GLP-1 market is no longer simply a weight-loss story.
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Amgen (AMGN) closed at $407.27 in the latest trading session, marking a -3.38% move from the prior day.
These dow jones stocks are moving in today's session
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
What Is The Options Market Telling Us About Eli Lilly Stock?
Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
2 Profitable Stocks with Exciting Potential and 1 We Find Risky
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Recombinant Proteins Market - Global Strategic Business Report: Sales Hit to $5.8 Billion by 2030 - Benchmark Thermo Fisher Scientific, Merck KGaA, Amgen, Bio-Techne and GenScript Biotech Amid Tariff Disruption
Demand for biologics, targeted therapies and personalized medicine is rising, while AI-led protein design and scalable bioprocessing unlock new opportunities.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global recombinant proteins market was valued at US$3.3 billion in 2024 and is projected to reach US$5.8 billion by 2030, expanding at a compound annual growth rate of 10.2%. Ma
Which dow jones stocks are moving on Tuesday?
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
Is Eli Lilly Stock a Good Fit For Your Portfolio Risk?
You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.
Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree?
Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.
Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
Keyron Appoints Former FDA Medical Device Center Director David Feigal as Board Chair
LONDON, September 29, 2026--Keyron, developer of the ForePass® fully reversible metabolic bypass platform for severe metabolic disease, today announced that David Feigal, MD, was appointed Board Chair effective September 21, 2026.
Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $500
Scotiabank analyst Louise Chen maintains Amgen (NASDAQ:AMGN) with a Sector Outperform and raises the price target from $450 to $500.
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?
On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren’s disease. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in systemic disease activity. Following the announcement, Citi reaffirmed a Neutral rating and $405 price target on Amgen. While Citi noted that the results […]
Amgen (AMGN), What Is Behind The Fresh Attention?
Amgen (AMGN) just reported positive topline data from its Phase 3 OASIZ 301 trial of dazodalibep in Sjögren's disease, an update that puts fresh attention on the stock's autoimmune pipeline potential. Set against that clinical update, Amgen’s share price has climbed 15.5% over the past 90 days and 27.6% year to date, while the 1-year total shareholder return of 56.9% and 5-year total shareholder return of 131.0% point to strong longer term momentum building around the story. Spot emerging...
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche’s efforts to challenge obesity-market […]
Top dow jones movers in Monday's session
Curious about the dow jones stocks that are in motion on Monday? Join us as we explore the top movers within the dow jones index during today's session.
Uncover the latest developments among dow jones stocks in today's session.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.
Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus
Microsoft, Bloom Energy and Amgen highlight Zacks' latest market moves, with strong gains across Focus List, recommendation and dividend portfolios.
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected
Why Amgen’s Pipeline Just Got More Interesting
Amgen Inc. (NASDAQ:AMGN)’s experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease. After 48 weeks, patients with moderate-to-severe disease activity showed statistically significant and clinically meaningful improvements. Most adverse events were mild to moderate, and only a small number of patients stopped treatment. Sjögren’s affects about 1% of the global […]
Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back
Amgen Inc. (NASDAQ:AMGN) has sold its office campus in Deerfield, Illinois, for $151 million. The buyer is an entity tied to Mesirow, a financial services firm based in Chicago. Amgen is not leaving. It has signed a long-term lease to stay on the roughly 660,000-square-foot campus, where it occupies one of the three buildings. The […]
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.
Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.
2 Healthcare Stocks That Just Delivered Great News for Investors
And there could be more positive developments ahead.
Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal
Mesirow CEO Richard S. Price with 1 Horizon Way in Deerfield (Getty, Mesirow, Google Maps)An entity tied to Chicago financial services firm Mesirow bought the Amgen office complex in Deerfield in a sale-leaseback deal for $151 million. The deal for the property, which spans 660,000 square feet of office space in three buildings at 1 Horizon Way along I-294 in suburban Deerfield, is rare for a site of its 70-acre size, according to Crain’s. The suburbs still suffer from high vacancy rates and sha
Amgen (AMGN) Rises Higher Than Market: Key Facts
In the latest trading session, Amgen (AMGN) closed at $414.61, marking a +2.11% move from the previous day.
Exploring the top movers within the dow jones index during today's session.
Curious about the dow jones stocks that are in motion on Friday? Join us as we explore the top movers within the dow jones index during today's session.
Is LLY Stock Cheaper Than It Looks?
At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.
How To Build A $75,000 Dividend Portfolio With SCHD And 5 High-Yield Picks
Build a $75K dividend portfolio anchored by SCHD, enhanced with JEPI, VNG, and 8 quality stocks to boost yield, growth, and diversificationâread now.
Keystone To Launch India Business With Bengaluru As First Hub, Plans To Hire Talent & Increase Workforce Over Next Two Years
Keystone, a global advisory firm that guides the most critical technology and science-based platforms and ecosystems, today announced it is establishing Keystone India, with Bengaluru as its first hub in the country. The company plans to hire talent and expand its workforce in India over the next two years.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Bet on These 5 Dividend Growth Stocks Amid Rising Treasury Yields
Rising Treasury yields are reshaping market preferences, putting dividend growth stocks like EnerSys and Amgen in focus for income and growth.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
How Investors Are Reacting To Veeva Systems (VEEV) Expanding Agentic AI And Winning New Pharma Clients
In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM. Together, these developments highlight Veeva’s push to embed agentic AI across clinical, safety, quality, and commercial workflows, reinforcing its role as an end-to-end software partner for life sciences...
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with Amgen (NASDAQ:AMGN).
Stay informed with the top movers within the dow jones index on Thursday.
Curious about the top performers within the dow jones index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.
How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding
Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compounding cost over two decades is far steeper than most investors expect.
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Novo Nordisk A/Sâs 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.
UPLIZNA Market Poised for Growth Through 2034 as Expanding Indications and Rising Demand Drive Sales Opportunities
UPLIZNA growth is driven by new indications, global expansion, strong efficacy, differentiated CD19 targeting and twice-yearly dosing, though competition is intensifying.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "UPLIZNA Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The UPLIZNA sales forecast and market analysis report provides a comprehensive assessment of the therapy's commercial outlook across approved and potential autoimmune indication
Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease
Amgen recently reported positive topline Phase 3 OASIZ 301 results for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease, showing statistically significant and clinically meaningful ESSDAI improvements sustained through Week 48 with generally mild to moderate side effects. Because there are currently no approved disease‑modifying therapies for persistent systemic Sjögren’s, this potential first‑in‑class CD40L antagonist could address an important unmet treatment...
Amgen price target raised by Jefferies to $410 after positive Sjögren's data
Amgen Inc (NASDAQ:AMGN, XETRA:AMG)'s price target was raised to $410 from $367 by Jefferies after dazodalibep delivered positive Phase 3 results in patients with systemic Sjögren's disease. Jefferies said the drug, a CD40L antagonist, achieved a statistically significant and clinically...
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.
Stay informed with the top movers within the dow jones index on Wednesday.
Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Wednesday.
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets
Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO) stock dropped sharply on Monday after the company laid out new long-term goals that failed to convince investors it can hold its ground against fast-growing rivals in the weight loss drug market.
Amgen Stock Gains After Announcing Positive Phase 3 Sjögren’s Disease Trial Results
Key Stats for Amgen StockPrice change for Amgen stock in last 1 year: 43%$AMGN Stock Price as of Sep. 22: $41052-Week High: $447$AMGN Stock Price Target: $388What Happened?Amgen (AMGN) stock rose after the company shared positive Phase 3 trial results.
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva
Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness.
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 0.5% and the St
Tuesday's session: top gainers and losers in the dow jones index
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.
Discover which S&P500 stocks are making waves on Tuesday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.
Amgen reports a Phase 3 win with Sjögren’s drug candidate
Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.
AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’
In a trial in patients with Sjögren’s disease, Amgen’s dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems.
Stock Market Today: Dow Skids As Trump Threatens Iran; Medical Diagnostics Plays Swoon (Live Coverage)
Stock Market Today: The Dow Jones index was lower after President Trump threatened Iran at the UN. Apple stock is near a buy point.
Amgen (AMGN) Posted Positive Phase 3 Results In Sjögren's Disease
Amgen (NasdaqGS:AMGN) reported positive Phase 3 trial results for dazodalibep in Sjögren's disease, targeting a major unmet autoimmune need. The company described dazodalibep as a potential first-in-class therapy, following successful outcomes in patients with Sjögren's disease. Amgen received an FDA label update for IMDELLTRA in extensive-stage small cell lung cancer, reducing recommended patient monitoring times. The dazodalibep Phase 3 success and IMDELLTRA monitoring change both reshape...
These S&P500 stocks are moving in today's session
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.
Stock Market Today: Dow Slips But Apple Touches A Buy Point; Homebuilder, Retailer Funds Shine (Live Coverage)
Stock Market Today: The Dow Jones index reversed lower despite new U.S.-Iran peace hopes. Apple stock is trading near a buy point.
Amgen Boasts Success In Sjogren's; Shares Charge Ahead
Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.
Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data
Amgen's Phase 3 study shows dazodalibep significantly improves systemic disease activity in adults with Sjögren's disease.
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.
Amgen Announces Its Phase 3 OASIZ 301 Trial Of Dazodalibep To Treat Sjogren's Disease Meets Primary Endpoint, Shows Improvement In Systemic Disease Activity At Week 48
Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.The study met
Capitalize on the PEGylated Proteins Revenue Shift: Benchmark Amgen, Roche, Merck KGaA, Pfizer and Novo Nordisk to Secure Competitive ROI Through the Forecast Period
Site-specific PEGylation is enabling safer, longer-acting biologics, while demand in chronic disease, targeted therapies and biosimilars creates opportunities for services and reagents.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "PEGylated Proteins - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for PEGylated Proteins was estimated at US$2.0 Billion in 2025 and is projected to reach US$4.1 Billion by 2032, growing at a CAGR of 10.6% from 2
Novo defends diversification push as CEO eyes deals beyond obesity
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
Morgan Stanley flags Amgen's edge after heart-drug rival stumbles
A private meeting with Amgen management left Morgan Stanley with a very different read than the broader market’s.
Stock Market Today: Dow Up, Nasdaq Roars As Micron Tests Entry; Bessent Touts China Progress (Live Coverage)
The Dow Jones index rallies on the stock market today after Treasury Secretary Scott Bessent touts China talks. Nvidia stock climbs.
Stock Market Today: Nasdaq Roars As Micron Tests Entry; AMD In Buy Zone As It Eyes New High (Live Coverage)
The Dow Jones index rallies on the stock market today after Treasury Secretary Scott Bessent touts China talks. Nvidia stock climbs.
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan
VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.
Discover which dow jones stocks are making waves on Monday.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors
Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...
Stock Market Today: Dow Up As Alphabet Shines, Tech Fund Offers Entry; Oil Dips On Iran Hopes (Live Coverage)
Stock Market Today: The Dow Jones index rallies Monday as oil prices and Treasury yields drop. Nvidia and Google stock climb.
The Zacks Analyst Blog Highlights AMD, Linde, Amgen and INNOVATE
AMD's AI infrastructure demand is broadening as EPYC CPUs and Instinct accelerators gain traction, while Helios ramps and multigigawatt commitments boost visibility.
Novo shares slide as drugmaker lays out post-Wegovy growth strategy
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations. The answer may surprise investors who have been watching Merck's blockbuster momentum.
Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline Risks
Amgen’s updated analyst model now points to a fair value price target of US$388.03, compared with the prior US$371.93. This provides a slightly higher anchor for how the stock is being valued today. This shift comes as recent research highlights a split view, with some analysts focusing on strong commercial execution and others stressing that questions around patents and the pipeline may already be reflected in the share price. As you read on, you will see how to interpret these moving...
Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Amgen (AMGN) closed at $385.65, indicating a +1.55% shift from the previous trading day.
What Would It Take For Eli Lilly Stock To Keep Climbing?
Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.
Top Research Reports for AMD, Linde & Amgen
AMD, Linde and Amgen highlight AI demand, contracted growth and drug launches, while supply, margin and pipeline risks remain key factors.
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.
Which dow jones stocks are moving on Friday?
Curious about the dow jones stocks that are in motion on Friday? Join us as we explore the top movers within the dow jones index during today's session.
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Bitcoin Tops $80,000, S&P 500 Slips as Yields Reclaim 5%: Stock Market Today
Crypto-linked equities ripped higher as Bitcoin cleared $80,000, but the S&P 500 slipped with the 10-year Treasury yield back above 5%.
A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too
On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes. Analysts said Amgen’s olpasiran faces […]
Can Volume Keep Covering Eli Lilly's Price Cuts?
Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.
Amgen Stock Fell 10% in a Day on a Drug It Doesn’t Own. Is It Time to Buy AMGN?
Key Stats for Amgen StockCurrent Price: $375. 65Target Price (Mid): ~$495Street Target: ~$388Potential Total Return: ~32%Annualized IRR: ~6.
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.
Critics Warn of AI-Driven Disaster. Anthropic and Novo Are Betting on the Opposite.
Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.
Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022
The pharmaceutical giant's track record in past bear markets is fairly impressive.
Explore the top gainers and losers within the dow jones index in today's session.
Curious about the top performers within the dow jones index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Will AI Save the Pharma Industry Billions? Novo’s Anthropic Deal Is Betting on It.
Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.
Why This Biotech Stock Just Got a Rare Double Upgrade
The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
Recently published Sjogren's Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Sjogren's syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
September Syndrome in Full Swing: 3 Picks to Safeguard Your Portfolio
September's market jitters highlight defensive stocks, ADM, AMGN and SUN, with low betas, high yields, raising 2026 guidance and improving earnings estimates.
Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities
Amgen (NASDAQ:AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns. Dittrich, who previou
Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Amgen Inc. (AMGN) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsThomas J.
4 Defensive Stocks to Take Refuge in as Consumer Sentiment Plummets
ADM, COCO, AMGN and CNC offer defensive exposure as inflation, oil prices and weak consumer sentiment fuel market volatility.
Leading Biotech Selects Veeva Vault CRM Globally
Veeva Systems (NYSE: VEEV) today announced that Amgen plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade.
Is This LLY Stock Dip Big Enough To Be Worth Buying?
Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved an update to the IMDELLTRA® (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting.
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.
Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. And since Amgen’s […]
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
What Moved Markets This Week
Weekly stock market recap: Oracle earnings beat, CPI inflation and 10-year Treasury yield jump move stocks.
Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential
Amgen (NASDAQ:AMGN) executives highlighted growth across its key commercial products, progress in late-stage development programs and a continued focus on profitability and cash returns during a Wells Fargo biotech and pharma discussion. Chief Financial Officer Thomas Dittrich, who recently returne
Amgen Drops 10% on a Trial It Didn't Even Run
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca
Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (NYSE:AZN) received a positive boost after their combination of Amgen’s Imdelltra and AstraZeneca’s Imfinzi significantly improved overall survival in a late-stage trial involving patients with extensive-stage small-cell lung cancer. The combination was tested as a maintenance treatment against Imfinzi alone in patients whose disease had not progressed after initial […]
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
The latest trading day saw Amgen (AMGN) settling at $382.47, representing a -2.25% change from its previous close.
Which dow jones stocks are moving on Thursday?
Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
Amgen Inc. (AMGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Amgen Inc. (AMGN) Wells Fargo 21st Annual Healthcare Conference September 10, 2026 11:00 AM EDTCompany ParticipantsThomas J.
Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls
Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls
Here Are Thursday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Amgen, AngloGold Ashanti, Caterpillar, Chewy, Meta Platforms, Novartis, NVIDIA, SK hynix, and More
Markets are taking a beating as crude oil surges past $100 and Treasury yields hit multi-year highs, setting up a make-or-break inflation report that could seal the Fed's next move. Wall Street analysts are already repositioning across semiconductors, biotech, and energy ahead of the fallout.
HSBC Downgrades Amgen to Hold, Lowers Price Target to $425
HSBC analyst Morten Herholdt downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and lowers the price target from $445 to $425.
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
Investing.com -- HSBC adjusted ratings and target prices across its biopharma coverage, citing "a lower sector additional risk premium" following a rally in the second quarter of 2026.
Amgen: Buy The Novartis-Driven Selloff (Rating Upgrade)
Amgen raised full-year 2026 revenue and EPS guidance, signaling improved confidence. Find out why AMGN stock is upgraded to buy.
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes
Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints […]
Buy the dip; favor U.S. utilities and consumer staples and discretionary: Matrix Asset Advisors CIO
David Katz of Matrix Asset Advisors says it is normal for markets to take a breather after a strong run, suggesting investors buy the dips if the market pulls back 3-5%. He favors U.S. utilities and sees opportunities in consumer staples and discretionary stocks, despite their recent underperformance.
What Eli Lilly Was Telling You While It Rationed Its Own Launches
Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m. ET on Tuesday, September 15, 2026. Jay Bradner, executive vice president, Research and Development, Artificial Intelligence and Data at Amgen, and Thomas Dittrich, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and th
Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Meets Major Goals
The Imdelltra-Imfinzi combination improved survival and response measures in a 563-patient late-stage lung-cancer trial.
Stock Market News for Sep 9, 2026
Wall Street ended lower as market participants weighed inflation concerns, rising oil prices and interest-rate expectations.
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study
Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) said a late-stage study of Imdelltra combined with Imfinzi produced improved outcomes in patients with extensive-stage small-cell lung cancer.
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday’s clinical data webcast.
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons
Crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, today, Sept. 8, 2026.
AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today’s Market
FEATURE Stocks declined on Tuesday as oil prices rose, renewing investor worries about hotter inflation and bolstering the case for the Federal Reserve to raise interest rates. Investor attention may turn to Apple on Wednesday when the company holds its iPhone launch event.
Stay informed with the top movers within the dow jones index on Tuesday.
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
Uncover the latest developments among S&P500 stocks in today's session.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.
Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says
Amgen's (AMGN) experimental heart drug olpasiran may still show a meaningful reduction in major card
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.
Amgen, Novartis, Qualcomn, Corning, Lumentum, and More Stocks That Explain Today’s Market
Stocks declined on Tuesday as oil prices rose, renewing investor worries about hotter inflation and bolstering the case for the Federal Reserve to hike interest rates. Investor attention may turn to Apple on Wednesday when the company holds its iPhone launch event. Artificial-intelligence stocks were advancing despite the market’s inflation worries.
AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test
The 563-patient study hit three efficacy endpoints, but investors still lack hazard ratios and regulatory timing.
Novartis Trial Failure Sparks Biopharma Options Frenzy
3 biopharma stocks seeing high options volume
Novartis Stock Tanks Following Third Major Pipeline Setback
Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions.
Stock Market Today: Dow Dives, Oil Spikes After Saudi Attacks; Amgen Swoons On These Results (Live Coverage)
Stock Market Today: The Dow Jones index sells off 500 points Tuesday, as oil prices jump on continued U.S.-Iran attacks. SK Hynix breaks out.
These S&P500 stocks are gapping in today's session
Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday
Amgen shares are following Novartis lower in the wake of disappointing clinical trial results.
One Stock Is Weighing Heavily on the Dow
The Dow lost 500 points early into Tuesday's trading session. Here's what's driving the loss. Most components in the blue chip index were in the red, but there was one name seeing the most dramatic downturn.
Why Novartis’ Drug Trial Results Are Blowing Up Amgen Stock
Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.
Qualcomm, Amgen, Novartis, Corning, Boeing, and More Stocks That Explain Today’s Market
Amgen falls following Swiss drugmaker Novartis’ disappointing trial data. Novartis trades sharply lower.
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.
Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)
Amgen (AMGN) drops after Novartisâ pelacarsen Phase 3 miss, pressuring olpasiranâs thesis amid patent cliffs. Click here to read my most recent analysis.
Intel upgraded, Reddit initiated: Wall Street's top analyst calls
Intel upgraded, Reddit initiated: Wall Street's top analyst calls
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on rival Lp(a) drug olpasiran.
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Amgen (NASDAQ: AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone. This study tested IMDELLTRA as a first-line maintenance treatment for people with extensive stage small cell lung cancer (
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
WILMINGTON, Del., September 08, 2026--Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who had not progressed following standard induction treatment w
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death
What's Going On With Amgen Stock Tuesday?
AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical outlook, and analyst price targets
These S&P500 stocks are moving in today's pre-market session
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus
Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Amgen, Baidu, Best Buy, Circle Internet, Corning, Intel, Lockheed Martin SpaceX, TeraWulf and More
Wall Street returns from summer vacation to a market suddenly bracing for a rate hike, with fresh analyst calls on Intel, Lockheed Martin, Amgen, and SpaceX adding more pressure points to an already tense week.
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment
AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 trial data for lung cancer and COPD.
The Stock Market Has Ignored the Iran Conflict. Why That’s About to Change.
Brent crude nears $100, Amgen stock falls, SpaceX lands $3 trillion valuation, and the latest on the Amazon plane crash.
BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts
Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies.
Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade
Amgen (NASDAQ:AMGN) shares fell 4. 7% to $416.
NewAmsterdam Pharma: Potential Coupled With Uncertainty
NewAmsterdam Pharma (NAMS) has seen a near 40% stock pullback post-Merckâs Lipfendra approval, but retains multi-blockbuster potential with obicetrapib. Read the latest on the stock here.
Dow Futures Slump as Middle East Fears Grip Markets
Stocks were on track to open lower on Tuesday as investors fretted about the disruption of oil shipments through the Strait of Hormuz. Dow Jones Industrial Average futures slumped 393 points, or 0.7%. S&P 500 futures dropped 0.2%.
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.
BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450
BMO Capital analyst Evan David Seigerman downgrades Amgen (NASDAQ:AMGN) from Outperform to Market Perform and maintains the price target from $450 to $450.
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $400 Price Target
Cantor Fitzgerald analyst Carter Gould reiterates Amgen (NASDAQ:AMGN) with a Neutral and maintains $400 price target.
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar
Novartis lowered the target biomarker without reducing events; olpasiran must prove the mechanism can still deliver.
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?
Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence Now Available. Tracks 870+ Organizations and 1,400+ Drugs Across the Full Bi/Multispecific Oncology Pipeline
One-Year Analytical Tool Delivers Near-Real-Time Pipeline Alerts on 481 Targets, 350 Deals, and 1,100+ Funding Rounds as Amgen, Roche, and J&J Lead a Field That Saw 278 New Drugs in 2024/25 AloneDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence" has been added to ResearchAndMarkets.com's offering. Bi/Multispecific Drugs in Oncology Analytical Tool Delivers Near-Real-Time Intelligence for Oncology Drug
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?
In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.
Dividend Champion, Contender, And Challenger Highlights: Week September 6
Explore this weekâs dividend updates for Dividend Champions, Contenders & Challengersâsee dividend changes, upcoming ex-dividend and pay dates.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.
Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?
Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous heart attack or stroke and followed them for a median of 4.6 years. The mortality reduction began to appear […]
Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $435
Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $400 to $435.
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 23.2% over the past six months, topping the S&P 500 by 11.5 percentage points.
Discover which dow jones stocks are making waves on Thursday.
Stay informed about the performance of the dow jones index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dogs Of The Dow: No Buys And Few Worth Watching
Dogs of the Dow look overvalued, with no must-buy dividend signals.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-13 | Khosla Rachna | -1,252 | - | - |
| 2026-08-13 | Khosla Rachna | -1,252 | $416.4256 | $521,365 |
| 2026-08-13 | Khosla Rachna | +1,252 | $162.6 | $203,575 |
| 2026-08-11 | Khosla Rachna | -2,000 | $412.567 | $825,134 |
| 2026-08-07 | Busch Matthew C. | +730 | - | - |
| 2026-08-07 | Drake Michael V | +64 | - | - |
| 2026-08-07 | ISHRAK OMAR | +85 | - | - |
| 2026-08-07 | HOLLEY CHARLES M | +103 | - | - |
| 2026-08-06 | Miller Derek | -1,821 | - | - |
| 2026-08-06 | Miller Derek | -2,069 | - | - |
| 2026-08-06 | Miller Derek | -1,821 | $402.5444 | $733,033 |
| 2026-08-06 | Miller Derek | +1,821 | $177.46 | $323,155 |
| 2026-08-06 | Miller Derek | -2,069 | $402.5444 | $832,864 |
| 2026-08-06 | Miller Derek | +2,069 | $162.6 | $336,419 |
| 2026-08-06 | Grygiel Nancy A. | -1,000 | - | - |
| 2026-08-06 | Grygiel Nancy A. | -1,970 | - | - |
| 2026-08-06 | Grygiel Nancy A. | -1,000 | $402.1601 | $402,160 |
| 2026-08-06 | Grygiel Nancy A. | +1,000 | $177.31 | $177,310 |
| 2026-08-06 | Grygiel Nancy A. | -1,970 | $402.1601 | $792,255 |
| 2026-08-06 | Grygiel Nancy A. | +1,970 | $177.46 | $349,596 |
| 2026-05-19 | Klotman Mary E. | +665 | - | - |
| 2026-05-19 | Drake Michael V | +665 | - | - |
| 2026-05-19 | Druker Brian | +665 | - | - |
| 2026-05-19 | Austin Wanda M | +665 | - | - |
| 2026-05-19 | ISHRAK OMAR | +665 | - | - |
| 2026-05-19 | Garland Greg C. | +665 | - | - |
| 2026-05-19 | Jacks Tyler | +665 | - | - |
| 2026-05-19 | Kullman Ellen Jamison | +665 | - | - |
| 2026-05-19 | MILES AMY E | +665 | - | - |
| 2026-05-19 | HOLLEY CHARLES M | +665 | - | - |
| 2026-05-19 | ECKERT ROBERT | +665 | - | - |
| 2026-05-07 | Bradner James E. | -446 | $331.11 | $147,675 |
| 2026-05-07 | Busch Matthew C. | -41 | $331.11 | $13,576 |
| 2026-05-07 | Miller Derek | -151 | $331.11 | $49,998 |
| 2026-05-07 | Khosla Rachna | -93 | $331.11 | $30,793 |
| 2026-05-07 | Grygiel Nancy A. | -88 | $331.11 | $29,138 |
| 2026-05-07 | Griffith Peter H. | -556 | $331.11 | $184,097 |
| 2026-05-07 | REESE DAVID M | -556 | $331.11 | $184,097 |
| 2026-05-07 | Santos Esteban | -522 | $331.11 | $172,839 |
| 2026-05-07 | Gordon Murdo | -615 | $331.11 | $203,633 |
| 2026-05-07 | Bradway Robert A | -2,079 | $331.11 | $688,378 |
| 2026-05-07 | Graham Jonathan P | -499 | $331.11 | $165,224 |
| 2026-05-06 | Busch Matthew C. | -50 | $329.59 | $16,480 |
| 2026-05-06 | Bradner James E. | -407 | $329.59 | $134,143 |
| 2026-05-06 | Miller Derek | -123 | $329.59 | $40,540 |
| 2026-05-06 | Khosla Rachna | -79 | $329.59 | $26,038 |
| 2026-05-06 | Grygiel Nancy A. | -76 | $329.59 | $25,049 |
| 2026-05-06 | Griffith Peter H. | -502 | $329.59 | $165,454 |
| 2026-05-06 | REESE DAVID M | -454 | $329.59 | $149,634 |
| 2026-05-06 | Santos Esteban | -427 | $329.59 | $140,735 |
| 2026-05-06 | Gordon Murdo | -502 | $329.59 | $165,454 |
| 2026-05-06 | Bradway Robert A | -1,702 | $329.59 | $560,962 |
| 2026-05-06 | Graham Jonathan P | -408 | $329.59 | $134,473 |
| 2026-05-05 | Busch Matthew C. | +2,969 | $329.59 | $978,553 |
| 2026-05-05 | Busch Matthew C. | +455 | - | - |
| 2026-05-05 | Bradner James E. | +21,773 | $329.59 | $7,176,163 |
| 2026-05-05 | Bradner James E. | +3,337 | - | - |
| 2026-05-05 | Drake Michael V | +80 | - | - |
| 2026-05-05 | Miller Derek | +5,938 | $329.59 | $1,957,105 |
| 2026-05-05 | Miller Derek | +910 | - | - |
| 2026-05-05 | Khosla Rachna | +3,266 | $329.59 | $1,076,441 |
| 2026-05-05 | Khosla Rachna | +500 | - | - |
| 2026-05-05 | Grygiel Nancy A. | +3,167 | $329.59 | $1,043,812 |
| 2026-05-05 | Grygiel Nancy A. | +485 | - | - |
| 2026-05-05 | Griffith Peter H. | +23,752 | $329.59 | $7,828,422 |
| 2026-05-05 | Griffith Peter H. | +3,640 | - | - |
| 2026-05-05 | REESE DAVID M | +19,002 | $329.59 | $6,262,869 |
| 2026-05-05 | REESE DAVID M | +2,912 | - | - |
| 2026-05-05 | Santos Esteban | +17,814 | $329.59 | $5,871,316 |
| 2026-05-05 | Santos Esteban | +2,730 | - | - |
| 2026-05-05 | Gordon Murdo | +23,752 | $329.59 | $7,828,422 |
| 2026-05-05 | Gordon Murdo | +3,640 | - | - |
| 2026-05-05 | ISHRAK OMAR | +106 | - | - |
| 2026-05-05 | Bradway Robert A | +79,176 | $329.59 | $26,095,618 |
| 2026-05-05 | Bradway Robert A | +12,136 | - | - |
| 2026-05-05 | Graham Jonathan P | +17,022 | $329.59 | $5,610,281 |
| 2026-05-05 | Graham Jonathan P | +2,609 | - | - |
| 2026-05-05 | HOLLEY CHARLES M | +129 | - | - |
| 2026-05-04 | Grygiel Nancy A. | -1,237 | $323.7272 | $400,451 |
| 2026-05-02 | Busch Matthew C. | -38 | $329.82 | $12,533 |
| 2026-05-02 | Busch Matthew C. | -30 | $329.82 | $9,895 |
| 2026-05-02 | Miller Derek | -198 | $329.82 | $65,304 |
| 2026-05-02 | Miller Derek | -167 | $329.82 | $55,080 |
| 2026-05-02 | Khosla Rachna | -108 | $329.82 | $35,621 |
| 2026-05-02 | Khosla Rachna | -117 | $329.82 | $38,589 |
| 2026-05-02 | Grygiel Nancy A. | -116 | $329.82 | $38,259 |
| 2026-05-02 | Grygiel Nancy A. | -126 | $329.82 | $41,557 |
| 2026-05-02 | Griffith Peter H. | -687 | $329.82 | $226,586 |
| 2026-05-02 | Griffith Peter H. | -746 | $329.82 | $246,046 |
| 2026-05-02 | REESE DAVID M | -687 | $329.82 | $226,586 |
| 2026-05-02 | REESE DAVID M | -746 | $329.82 | $246,046 |
| 2026-05-02 | Santos Esteban | -641 | $329.82 | $211,415 |
| 2026-05-02 | Santos Esteban | -697 | $329.82 | $229,885 |
| 2026-05-02 | Gordon Murdo | -763 | $329.82 | $251,653 |
| 2026-05-02 | Gordon Murdo | -830 | $329.82 | $273,751 |
| 2026-05-02 | Bradway Robert A | -2,426 | $329.82 | $800,143 |
| 2026-05-02 | Bradway Robert A | -2,631 | $329.82 | $867,756 |
| 2026-05-02 | Graham Jonathan P | -610 | $329.82 | $201,190 |
| 2026-05-02 | Graham Jonathan P | -647 | $329.82 | $213,394 |
| 2026-03-16 | Busch Matthew C. | -327 | $366.21 | $119,751 |
| 2026-03-16 | Miller Derek | -1,616 | $366.21 | $591,795 |
| 2026-03-16 | Khosla Rachna | -707 | $366.21 | $258,910 |
| 2026-03-16 | Grygiel Nancy A. | -787 | $366.21 | $288,207 |
| 2026-03-16 | Griffith Peter H. | -5,748 | $366.21 | $2,104,975 |
| 2026-03-16 | REESE DAVID M | -6,022 | $366.21 | $2,205,317 |
| 2026-03-16 | Santos Esteban | -5,621 | $366.21 | $2,058,466 |
| 2026-03-16 | Gordon Murdo | -6,691 | $366.21 | $2,450,311 |
| 2026-03-16 | Bradway Robert A | -21,294 | $366.21 | $7,798,076 |
| 2026-03-16 | Graham Jonathan P | -5,353 | $366.21 | $1,960,322 |
| 2026-03-04 | Bradway Robert A | -119,782 | - | - |
| 2026-03-04 | Bradway Robert A | -84,285 | $379.27 | $31,966,772 |
| 2026-03-04 | Bradway Robert A | +119,782 | $156.35 | $18,727,916 |
| 2026-03-03 | Busch Matthew C. | +938 | - | - |
| 2026-03-03 | Miller Derek | +3,484 | - | - |
| 2026-03-03 | Khosla Rachna | +1,876 | - | - |
| 2026-03-03 | Grygiel Nancy A. | +2,010 | - | - |
| 2026-03-03 | Griffith Peter H. | +12,063 | - | - |
| 2026-03-03 | REESE DAVID M | +12,063 | - | - |
| 2026-03-03 | Santos Esteban | +11,259 | - | - |
| 2026-03-03 | Gordon Murdo | +13,403 | - | - |
| 2026-03-03 | Bradway Robert A | +42,657 | - | - |
| 2026-03-03 | Graham Jonathan P | +10,723 | - | - |
| 2026-02-26 | Santos Esteban | -24,291 | - | - |
| 2026-02-26 | Santos Esteban | -30,501 | - | - |
| 2026-02-26 | Santos Esteban | -24,291 | $379.1173 | $9,209,138 |
| 2026-02-26 | Santos Esteban | +24,291 | $177.46 | $4,310,681 |
| 2026-02-26 | Santos Esteban | -30,501 | $379.1173 | $11,563,457 |
| 2026-02-26 | Santos Esteban | +30,501 | $162.6 | $4,959,463 |
| 2026-02-19 | Busch Matthew C. | -1,000 | $375.79 | $375,790 |
| 2026-02-09 | Bradner James E. | -953 | $384.32 | $366,257 |
| 2026-02-09 | Bradner James E. | -2,151 | $384.32 | $826,672 |
| 2025-11-20 | Grygiel Nancy A. | -1,639 | - | - |
| 2025-11-20 | Grygiel Nancy A. | -1,500 | - | - |
| 2025-11-20 | Grygiel Nancy A. | -1,639 | $337.2625 | $552,773 |
| 2025-11-20 | Grygiel Nancy A. | +1,639 | $162.6 | $266,501 |
| 2025-11-20 | Grygiel Nancy A. | -1,500 | $337.2625 | $505,894 |
| 2025-11-20 | Grygiel Nancy A. | +1,500 | $177.46 | $266,190 |
| 2025-11-12 | Khosla Rachna | -890 | $336.2422 | $299,256 |
| 2025-11-12 | Gordon Murdo | -6,879 | $336.8326 | $2,317,071 |
| 2025-11-12 | REESE DAVID M | -309 | - | - |
| 2025-11-11 | REESE DAVID M | -6,490 | - | - |
| 2025-11-07 | Drake Michael V | +219 | - | - |
| 2025-11-07 | ISHRAK OMAR | +219 | - | - |
| 2025-11-07 | HOLLEY CHARLES M | +265 | - | - |
| 2025-11-05 | Busch Matthew C. | -202 | $296.7 | $59,933 |
| 2025-11-05 | Khosla Rachna | -226 | $296.7 | $67,054 |